Clinical Trial Update: Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 [Phase 3]

View source ↗

Summary

Open-label extension and safety study of etrolizumab in Crohn's disease patients previously enrolled in the GA29144 phase III trial has terminated, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Etrolizumab (etrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-12-02